EE504 Cost-Utility Analysis Comparing Direct Oral Anticoagulant (DOAC) and Low-Molecular-Weight Heparin (LMWH) Therapies for Cancer-Associated Thrombosis (CAT) Treatment in the United States

Abstract

Cancer patients are at high risk of developing VTE. DOACs have been shown to prevent more VTE events and cause more bleeding events than LMWHs. With the addition of DOACs in the treatment guidelines and publishing of new clinical data, an updated study evaluating the cost-effectiveness of DOACs compared to LMWHs for CAT from the United States payer and societal perspectives is needed.